Perfusion radiology market seen reaching $7.89B by 2032

By AI, Created 10:39 AM UTC, May 20, 2026, /AGP/ – Maximize Market Research says the global perfusion radiology market was valued at $4.25 billion in 2024 and is projected to reach $7.89 billion by 2032. The report points to rising stroke and cardiovascular disease, plus AI-driven imaging tools and new PET tracers, as the main growth drivers.

Why it matters: - Perfusion radiology is becoming more central to stroke triage, cardiac imaging and oncology workflows as hospitals seek faster blood-flow assessment. - The market’s projected rise to $7.89 billion by 2032 signals growing demand for advanced imaging systems, software and radiotracers. - Higher adoption can affect care speed, diagnostic accuracy and access to real-time imaging in hospitals and diagnostic centers.

What happened: - Maximize Market Research estimated the global perfusion radiology market at $4.25 billion in 2024. - The firm projects the market will reach $7.89 billion by 2032, implying an 8.4% compound annual growth rate. - The report was published April 29, 2026. - The analysis covers CT perfusion, MRI perfusion and nuclear medicine perfusion across neurology, cardiology, oncology and other uses. - The report says hospitals and clinics are the main end users. - The U.S. market was valued at about $2.8 billion in 2024, making North America the largest regional market. - A full sample copy of the report is available online. - The full market report is also available online.

The details: - Rising stroke, ischemic heart disease and brain tumor incidence is driving CT and MRI perfusion adoption. - The report cites ischemic heart disease at 2,275.9 DALYs per 100,000 globally in 2023. - Clinical demand for sub-hour stroke triage is expanding procedure volumes. - AI-integrated diagnostic workflows are broadening reimbursement frameworks in North America, Europe and Asia-Pacific. - High capital costs remain a barrier for mid-tier and rural facilities in low- and middle-income countries. - Regulatory differences across FDA, CE Mark and CDSCO markets can extend procurement timelines and raise compliance costs. - Shortages of radiologists and nuclear medicine technologists also limit throughput. - FDA approvals of new PET tracers, including GE HealthCare’s Flurpiridaz F-18 in 2024, are opening premium cardiac imaging opportunities. - Asia-Pacific healthcare buildout and Southeast Asia’s cardiovascular burden are creating new deployment opportunities. - AI-driven automated perfusion quantification is reducing dependence on radiologists in some settings. - CT perfusion leads the market by type because of established stroke protocols and broad hospital adoption. - Neurology is the largest application segment. - Portable and mobile systems are expanding bedside and point-of-care use in emergency, ICU and rural settings.

Between the lines: - The report frames perfusion radiology as moving from a specialized tool to a core decision engine for acute and chronic disease management. - AI appears to be the main competitive lever because it can cut analysis time and lower staffing pressure. - New radiotracers may push cardiac perfusion into a higher-value segment with better imaging precision and lower radiation exposure than older SPECT approaches. - Asia-Pacific looks positioned as the main growth frontier because infrastructure investment is rising faster there than in mature markets. - Competition is concentrating around AI software, radiotracer pipelines and portable imaging platforms rather than around basic scanner hardware alone.

What’s next: - North America is expected to remain the largest market through 2032, supported by stroke infrastructure, reimbursement and advanced imaging capacity. - Asia-Pacific is projected to be the fastest-growing region as China, India, Japan and South Korea expand healthcare infrastructure. - The report highlights India’s more than 1.8 million annual stroke cases and government health programs, including PM-JAY, as growth catalysts. - Companies investing in AI-native software, mobile systems and regional partnerships are likely to be best positioned as adoption widens. - GE HealthCare, Siemens Healthineers, Philips, Canon Medical Systems and Abbott Laboratories are identified as leading competitors. - Other named players include Medtronic, Boston Scientific, Edwards Lifesciences, Terumo Corporation, Fresenius Medical Care, Getinge, LivaNova, Johnson & Johnson, B. Braun Melsungen AG, Zimmer Biomet and Abiomed.

The bottom line: - Perfusion radiology is set to grow steadily through 2032, with stroke care, AI automation and new tracers driving the next phase of demand.